High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use-Reference-Cited by-同舟云学术

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use

Published:2020-06-23 Issue:5 Volume:4 Page:964-969
ISSN:2397-9070
Container-title:JGH Open
language:en
Short-container-title:JGH Open

Author:

Tamori Akihiro¹^ORCID,Uchida‐Kobayashi Sawako¹,Kozuka Ritsuzo¹,Motoyama Hiroyuki¹,Yoshida Kanako¹,Odagiri Naoshi¹,Kotani Kohei¹,Kawamura Etsushi¹,Fujii Hideki²,Hagihara Atsushi¹,Enomoto Masaru¹,Kawada Norifumi¹

Affiliation:

1. Department of Hepatology, Graduate School of Medicine Osaka City University Osaka Japan

2. Department of Premier Preventive Medicine, Graduate School of Medicine Osaka City University Osaka Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jgh3.12376

Reference25 articles.

1. Hepatitis C

2. Current activities and future directions of comprehensive hepatitis control measures in Japan: The supportive role of the Hepatitis Information Center in building a solid foundation

3. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries

4. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High prevalence of hepatitis C virus among criminals in rehabilitation facilities in Japan;Journal of Infection and Chemotherapy;2024-05

2. A single site study to investigate the current prevalence of anti‐hepatitis C virus antibody among substance use disorder patients in Hiroshima—Insufficient testing and diagnosis;Neuropsychopharmacology Reports;2023-05-16

3. Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study;Internal Medicine;2022-10-15

4. Safety and effectiveness of glecaprevir/pibrentasvir in patients with chronic hepatitis C or compensated cirrhosis in daily clinical practice: a drug-use results survey;Kanzo;2022-03-01